All News

Meral K. El Ramahi, MD Tweet
MeralElRamahiMD
ABS0433: ⭐️Older adults w/ RA less likely to receive tx w/ DMARDs despite being well tolerated and effective ➡️Retrospect, obs using Medicare data ➡️At least 66 yo old w/ new dx of late-onset RA (LORA) 🚩If no contraindications, start DMARDs early in LORA! #ACR23 @RheumNow https://t.co/ChalcgtS2O
Mike Putman Tweet
EBRheum
Super interesting study re: impact of ORAL SURVEILLANCE on prescribing Post safety report, JAK pts shifted younger w/lower comorbidities (esp CVD) I know many have mixed feelings, but I believe in the risk & support this type of shift @RheumNow Abstr0435 #ACR23 https://t.co/EBg9VOIbj1
Meral K. El Ramahi, MD Tweet
MeralElRamahiMD
ABS0450 ⭐️Baricitinib non-inferior as well as superior to TNFi in terms of ACR50 response @ 12w in real world csDMARD refractory RA patients ➡️open-label, T2T w/ Baricitinib (n=102) vs TNFi (n=97) ➡️DAS28-CRP remission (<0.6) in 74% of Bari vs 47% of TNFi #ACR23 @RheumNow https://t.co/yydS20hNzM
Adela Castro Tweet
AdelaCastro222
ARDs increase risk for CVE in pregnancy, the highest being APS, SLE (with LN and APS) and RA. Close monitoring not only during but also after pregnancy is required. #Plenary #ACR23 https://t.co/W3CSjccSno
Richard Conway Tweet
Phase 2 RCT of TLL-018 (JAK1/TYK2i) vs Tofa in RA. 101 patients. ACR50 72% vs 42%. 83% of tofa-IR achieved ACR50 on TLL-018. Can't wait for the phase 3 data! Abstr#0840 #ACR23 @RheumNow #ACRbest https://t.co/wjGx4Edxyb https://t.co/n6CL8G01Wo
Dr. Antoni Chan Tweet
Finger fold index (FFI) calculated by deep neural network model reliable for metrical analysis and detection of swelling in RA with 91% accuracy. Mean FFI significantly higher in RA vs healthy controls PIP joints @marcblanchard23 Abst#0402 #ACR23 @RheumNow https://t.co/jmPvwzf2m8 https://t.co/DOZoV0xSsd
David Liew Tweet
drdavidliew
TLL-018, the dual JAK1/Tyk2 inhibitor which caused all the chatter at #EULAR2023, now with more full data showing it absolutely smash tofacitinib in RA, with similar safety. “This is a spectacular compound - unbelievably spectacular” - Roy Fleischmann #ACR23 ABST0840 @RheumNow https://t.co/nIKQb4yYrJ
David Liew Tweet
drdavidliew
More on TLL-018 How? A: Everyone surprised. But maybe dual mech benefits re: pain via IFN Where’s the multinational RCT in RA? A: Priority on rapid registration in China, quickly. But ph2 trials for psoriasis happening in US, results so far look consistent. #ACR23 @RheumNow
Aurelie Najm Tweet
What if we deliver TNFi to the wrong place? Delivery of ETA to peripheral lymphatics instead of subcut through a wearable device in 10pts showed: 1- is Safe 2-Reduces DAS28 (but more TJC than SJC) To be confirmed in larger and controlled study! @RheumNow #ACR23 ABST0838 https://t.co/IUPpFwjjbj
Aurelie Najm Tweet
Ph2a Nipocalumab: FcRn blocker IV15mg/kg TNF IR RA 32 pts Delta DASCRP -1 vs -0.5 PBO ACR50 20% vs 0 PBO DAS Remission 40% vs 16% Only in ACPA+ pts SAEs 1 infusion related reaction Not extremely convincing alone Currently studied in combination w/ TNFi @RheumNow #ACR23 ABST0839 https://t.co/6wTu2ellhN
Richard Conway Tweet
Ross et al. Fascinating study of infusion of etanercept into lymphatics in RA in inadequate responders to s/c etanercept. DAS28(CRP) reduced 5.40±0.16 to 3.55±0.21, PGA of Disease Activity and Pain decreased by 66% and 77%. Abstr#0838 #ACR23 @RheumNow https://t.co/RIMCS3nmy6 https://t.co/U2689atvmj
Richard Conway Tweet
APIPPRA trial of abatacept to prevent RA in sero+ arthralgia. Picture paints a thousand words - big difference at week 52 (on abatacept) and watch those lines converge Abstr#0835 #ACR23 #ACRbest @RheumNow https://t.co/cwX389TUZN https://t.co/2CQHYlW0nq
Richard Conway Tweet
Baker et al. Danish registry study. Truncal vagotomy increases risk RA (but not OA), HR 2.62 (95% CI 1.47-4.67). Support for vagus nerve stimulation in RA? Abstr#0836 #ACR23 @RheumNow https://t.co/SbphSMLHc7 https://t.co/93SfyGizLt
Aurelie Najm Tweet
Inflammatory reflex suggests role of vagal nerve in inflammation regulation Danish database Truncal vagotomy 2000+ pts matched w/ 22000+ = Increase risk for RA HR 2.6 Not the case for supras elective vagotomy (HR 1) No influence on OA @RheumNow #ACR23 ABST0836 https://t.co/3ThYP1nKTe
Richard Conway Tweet
Here's the counterpoint to the previous positive tweet on vagal nerve stimulation in RA. The previously promising data on auricular vagus stimulation falls flat on further study Abstr#0837 #ACR23 @RheumNow https://t.co/APnrPhWA9q https://t.co/adA0H1VETt
Aurelie Najm Tweet
This is particularly interesting considering this 👇🏼👇🏼 First RCT of NI auricular vagal nerve stimulation did not meaningfully improve RA disease activity or outcomes. No SAEs Is this supporting the need for other VNS modalities? @RheumNow #ACR23 ABST0837 https://t.co/yFcMPoSc31 https://t.co/G069XwUyAz
Aurelie Najm Tweet
What is D2T PsA? A proposal of definition in ABST0777 Thoughts: A lot of features are extrapolated from the EULAR RA definition RA & PsA population are hardly comparable Lack of emphasis more problematic domains ie. dactylitis Further work is required @RheumNow #ACR23 https://t.co/A28e6XBME3
David Liew Tweet
drdavidliew
Fascinating how upadacitinib may well have an effect on pain in RA, beyond inflammation. Now seen similar for bari in RA & guselkumab in PsA. And, if real, for some people could be a massive get. Love to see dedicated studies SELECT-COMPARE post-hoc #ACR23 ABST0429 @RheumNow https://t.co/Tk278mGJYY
×